Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Licofelone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.84 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.84 |
| ▸ | PTGES | O14684 | 3/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.84 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Licofelone SCHEMBL237833 | 0.92 | ALOX5 (1.00) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL1843506 | 0.88 | PTGES (0.92) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL7737421 | 0.86 | PTGES (0.88) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL4087247 | 0.86 | PTGES (0.83) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL1393673 | 0.85 | PTGES (0.83) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL9458992 | 0.85 | ALOX5 (0.86) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL5560426 | 0.84 | PTGES (0.85) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL13697422 | 0.84 | PTGES (0.85) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| SCHEMBL19499839 | 0.84 | PTGES (0.85) | PTGESALOX5PTGS1ALOX5APPTGS2 | |
| Licofelone SCHEMBL7738810 | 0.83 | PTGES (0.83) | PTGESALOX5PTGS1ALOX5APPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010261-A1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-01-12 | — | — | US | claimed |
| EP-2350082-A1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | c-a-i-r biosciences GmbH (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010049525-A1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | C-A-I-R BIOSCIENCES GMBH (DE) | 2010-05-06 | — | — | WO | claimed |
| EP-2350082-B1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | C A I R BIOSCIENCES GMBH (DE) | 2015-01-14 | — | — | EP | disclosed |
| US-8519155-B2 | Choline and tromethamine salt of licofelone | C-A-I-R BIOSCIENCES GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20120010261-A1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | C-A-I-R BIOSCIENCES GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| EP-2350082-A1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | c-a-i-r biosciences GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010049525-A1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | C-A-I-R BIOSCIENCES GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010261-A1 | CHOLINE AND TROMETHAMINE SALT OF LICOFELONE | ACHE, CHAT, LPCAT1 | PTGS1 2113/4885PTGS2 2229/4885PTGES 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.